Sten Madsbad

37.3k total citations · 7 hit papers
545 papers, 27.6k citations indexed

About

Sten Madsbad is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Physiology. According to data from OpenAlex, Sten Madsbad has authored 545 papers receiving a total of 27.6k indexed citations (citations by other indexed papers that have themselves been cited), including 327 papers in Endocrinology, Diabetes and Metabolism, 230 papers in Surgery and 170 papers in Physiology. Recurrent topics in Sten Madsbad's work include Diabetes Treatment and Management (207 papers), Diabetes Management and Research (146 papers) and Diet and metabolism studies (133 papers). Sten Madsbad is often cited by papers focused on Diabetes Treatment and Management (207 papers), Diabetes Management and Research (146 papers) and Diet and metabolism studies (133 papers). Sten Madsbad collaborates with scholars based in Denmark, United States and United Kingdom. Sten Madsbad's co-authors include Jens J. Holst, Thure Krarup, Tina Vilsbøll, Kirstine N. Bojsen‐Møller, Carsten Dirksen, Filip K. Knop, Carolyn F. Deacon, Aage Vølund, M. Toft-Nielsen and Mette Zander and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Sten Madsbad

530 papers receiving 26.5k citations

Hit Papers

Effect of 6-week course of glucagon-like peptide 1 on gly... 2001 2026 2009 2017 2002 2001 2001 2004 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
    2002 1.1k citations Sten Madsbad, Jens J. Holst et al. profile →
  2. Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
    2001 716 citations Thure Krarup, Carolyn F. Deacon et al. Diabetes profile →
  3. Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients
    2001 702 citations Sten Madsbad, Jens J. Holst et al. profile →
  4. Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy
    2004 625 citations Stephen C. Bain, Sten Madsbad et al. profile →
  5. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
    2021 287 citations J. Lundgren, Charlotte Janus et al. profile →
  6. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
    2024 105 citations Simon Birk Kjær Jensen, Rasmus Michael Sandsdal et al. profile →
  7. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment
    2024 56 citations Simon Birk Kjær Jensen, Rasmus Michael Sandsdal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sten Madsbad Denmark 87 17.0k 11.7k 7.1k 7.1k 2.9k 545 27.6k
Robert R. Henry United States 83 12.8k 0.7× 7.0k 0.6× 11.0k 1.5× 7.1k 1.0× 1.9k 0.7× 292 27.8k
Tina Vilsbøll Denmark 73 14.9k 0.9× 8.1k 0.7× 7.0k 1.0× 3.4k 0.5× 1.3k 0.4× 455 20.3k
Yutaka Seino Japan 71 11.2k 0.7× 7.2k 0.6× 8.5k 1.2× 3.1k 0.4× 2.4k 0.8× 558 22.4k
Filip K. Knop Denmark 74 12.4k 0.7× 7.7k 0.7× 6.0k 0.8× 3.7k 0.5× 1.4k 0.5× 552 18.8k
John E. Gerich United States 92 15.4k 0.9× 8.9k 0.8× 7.8k 1.1× 7.5k 1.1× 4.3k 1.5× 343 26.4k
Juris J. Meier Germany 69 12.0k 0.7× 8.1k 0.7× 5.9k 0.8× 2.5k 0.4× 2.5k 0.9× 208 17.2k
André Scheen Belgium 67 10.7k 0.6× 4.5k 0.4× 5.3k 0.7× 3.9k 0.6× 1.2k 0.4× 759 19.9k
Suad Efendić Sweden 65 9.1k 0.5× 6.8k 0.6× 6.1k 0.8× 3.5k 0.5× 2.5k 0.8× 399 18.6k
Henning Beck‐Nielsen Denmark 83 8.3k 0.5× 4.6k 0.4× 8.3k 1.2× 7.2k 1.0× 2.7k 0.9× 447 23.2k
Andrea Mari Italy 68 9.3k 0.5× 6.7k 0.6× 4.6k 0.7× 4.0k 0.6× 2.0k 0.7× 287 15.1k

Countries citing papers authored by Sten Madsbad

Since Specialization
Citations

This map shows the geographic impact of Sten Madsbad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sten Madsbad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sten Madsbad more than expected).

Fields of papers citing papers by Sten Madsbad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sten Madsbad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sten Madsbad. The network helps show where Sten Madsbad may publish in the future.

Co-authorship network of co-authors of Sten Madsbad

This figure shows the co-authorship network connecting the top 25 collaborators of Sten Madsbad. A scholar is included among the top collaborators of Sten Madsbad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sten Madsbad. Sten Madsbad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Madsbad, Sten & Jens J. Holst. (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs. 34(3). 197–215. 10 indexed citations
2.
Sjøberg, Kim A., Nicolai J. Wewer Albrechtsen, Michal Považan, et al.. (2024). The impact of short-term eucaloric low- and high-carbohydrate diets on liver triacylglycerol content in males with overweight and obesity: a randomized crossover study. American Journal of Clinical Nutrition. 120(2). 283–293. 14 indexed citations
3.
Kjeldsen, Sasha A. S., Amirsalar Samkani, Jan Frystyk, et al.. (2023). Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes. Journal of the Endocrine Society. 7(11). bvad122–bvad122. 5 indexed citations
4.
Gabe, M, Kirsa Skov‐Jeppesen, Lærke S. Gasbjerg, et al.. (2022). GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research. 176. 106058–106058. 32 indexed citations
5.
Jensen, Simon Birk Kjær, Charlotte Janus, J. Lundgren, et al.. (2022). Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nature Communications. 13(1). 4770–4770. 27 indexed citations
6.
Jensen, Simon Birk Kjær, Christian R. Juhl, Charlotte Janus, et al.. (2022). Insufficient sleep predicts poor weight loss maintenance after 1 year. SLEEP. 46(5). 8 indexed citations
7.
Almdal, Thomas, Peter Vestergaard, Louise Lundby‐Christensen, et al.. (2021). Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Osteoporosis International. 32(9). 1837–1848. 10 indexed citations
8.
Munk, J., et al.. (2021). Fractionated free fatty acids and their relation to diabetes status after Roux‐en‐Y gastric bypass: A cohort study. Physiological Reports. 9(2). e14708–e14708. 2 indexed citations
9.
Worm, Dorte, Sten Madsbad, & Dorte Lindqvist Hansen. (2019). Metabolic Health in Severely Obese Subjects: A Descriptive Study. Metabolic Syndrome and Related Disorders. 17(2). 115–119. 3 indexed citations
10.
Leiter, Lawrence A., Stephen C. Bain, Irene Hramiak, et al.. (2019). Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovascular Diabetology. 18(1). 73–73. 86 indexed citations
11.
Rosenstock, Julio, Louis Chaykin, Joerg Luedemann, et al.. (2018). Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration—SUSTAIN 1-5 and 7 Patient-Level Meta-analysis. Diabetes. 67(Supplement_1). 1 indexed citations
12.
Samkani, Amirsalar, Christian Anholm, Arne Astrup, et al.. (2018). The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial. Lipids in Health and Disease. 17(1). 295–295. 9 indexed citations
13.
Klefter, Oliver Niels, E. Hommel, Inger Christine Munch, et al.. (2016). Retinal characteristics during 1 year of insulin pump therapy in type 1 diabetes: a prospective, controlled, observational study. Acta Ophthalmologica. 94(6). 540–547. 15 indexed citations
14.
Schmidt, Julie Berg, Nikolaj Ture Gregersen, Mette S. Nielsen, et al.. (2013). The effect of Roux-en-Y gastric bypass surgery on energy expenditure and appetite: a randomized human study including “pair fed” control subjects. Obesity Facts. 6. 1 indexed citations
15.
Jørgensen, Nils B., Søren Jacobsen, Carsten Dirksen, et al.. (2012). Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. American Journal of Physiology-Endocrinology and Metabolism. 303(1). E122–E131. 252 indexed citations
16.
Rabøl, Rasmus, Robert Boushel, Thomas Almdal, et al.. (2010). Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obesity and Metabolism. 12(9). 806–814. 38 indexed citations
17.
Schmidt, Wolfgang E., Stephen Gough, Sten Madsbad, et al.. (2009). Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss. Diabetologia. 52. 5 indexed citations
18.
Schmitz, Ole, Birgitte Brock, Jørgen Rungby, & Sten Madsbad. (2006). [The place of Glitazones in the treatment of diabetes: after the PROactive study].. PubMed. 168(18). 1750–2.
19.
Krarup, Thure, et al.. (1979). Impaired response of pancreatic polypeptide to hypoglycaemia: an early sign of autonomic neuropathy in diabetics.. BMJ. 2(6204). 1544–1546. 46 indexed citations
20.
Madsbad, Sten, K. G. M. M. Alberti, Christian Binder, et al.. (1979). Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes.. BMJ. 2(6200). 1257–1259. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert R. Henry Breakdown of academic impact, for papers by Tina Vilsbøll Breakdown of academic impact, for papers by Yutaka Seino Breakdown of academic impact, for papers by Filip K. Knop Breakdown of academic impact, for papers by John E. Gerich Breakdown of academic impact, for papers by Juris J. Meier Breakdown of academic impact, for papers by André Scheen Breakdown of academic impact, for papers by Suad Efendić Breakdown of academic impact, for papers by Henning Beck‐Nielsen Breakdown of academic impact, for papers by Andrea Mari
Rankless by CCL
2026